Aegerion Pharmaceuticals, a specialty manufacturer focused on cardiovascular and metabolic disease, has appointed Peter Garrambone, Jr., to the company’s board of directors. Garrambone was previously a SVP, corporate strategic planning, at Pfizer.
 
SK&A, a marketing research firm, has promoted David Escalante, Jr., to president and CEO. Escalante was previously president and COO.